DRI Healthcare Comments on Juvmo's (tavapadon) FDA Approval
Tavapadon Conference Call
DRI Healthcare Announces US$316 Million Purchase of Tavapadon Royalty
DRI Healthcare Announces Receipt of Put Price on EKTERLY
Second Quarter 2026 Earnings Call
DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment
DRI Healthcare to Host Second Quarter 2026 Earnings Call and Webcast on August 10, 2026
DRI Healthcare Announces Exercise of Put Option on EKTERLY®
DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa™ (veligrotug-vvze)